Currently, ongoing in vivo and in vitro studies on MCC950, a small molecule capable of inhibiting the NLRP3 inflammasome, have demonstrated efficacy in mitigating liver damage in PBC [82]. The gene discussed is NLRP3; the disease is primary biliary cholangitis.